Work

Linc-02. Implementation of an Integrated Neuro-oncology Service: Clinicians’ Perspective on Conduct of Neuro-oncology Multidisciplinary Team Meeting From a Single-institution in Malaysia

Year: 2020

Type: conference-abstract

Abstract: INTRODUCTION Multidisciplinary Team (MDT) meetings are essential in the management of complex cancer cases. There are limited data regarding clinicians’ perception on conduct of neuro-oncology MDT meetings and its impact on clinical management. In University Malaya Medical Centre (UMMC), weekly neuro-oncology MDT meeting was established since 2013 to discuss adult and paediatric complex central nervous system tumour cases. OBJECTIVE To determine clinicians’ perception and level of satisfaction of neuro-oncology MDT meeting. METHODOLOGY Web-based questionnaire was distributed via e-mail to all neuro-oncology MDT clinicians at UMMC in April 2019. RESULT Eighteen out of 20 clinicians responded to the survey. Respondents were: neurosurgeons (n=5), adult oncologists (n=4), paediatric oncologists (n=3), radiologists (n=2), radiation oncologists (n=2) and pathologists (n=2). Majority of clinicians (65%) agreed at current weekly MDT meeting with maximum length of one hour duration and 75% of them suggested to discuss 5 to 10 cases during each meeting. Almost all of them (94.4%) preferred e-mail as method of communication to disseminate information before and after the meetings. MDT members expected 100% attendance from neurosurgeons. Fourteen (70%) clinicians agreed that patients/ parents/ carers do not receive copy of MDT meeting plans and only seven (35%) clinicians document MDT meeting plans in patients’ medical record. Overall, all clinicians felt that MDT meeting improved decision-making process, enhanced continuity of coordinated care and promoted good communication among team members. CONCLUSION The structure and logistics of neuro-oncology MDT meeting in UMMC are generally agreed upon. However, documentation of post-meeting plan and notification to patients need uniformity.

Source: Neuro-Oncology

DOI: 10.1093/neuonc/noaa222.437